Back to Search
Start Over
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
- Source :
-
Blood [Blood] 2003 May 01; Vol. 101 (9), pp. 3413-5. Date of Electronic Publication: 2003 Jan 09. - Publication Year :
- 2003
-
Abstract
- We explored the safety and efficacy of rituximab plus alemtuzumab in patients with relapsed or refractory lymphoid malignancies. Forty-eight patients were treated and were assessable for response (32 with chronic lymphocytic leukemia [CLL], 9 with CLL/prolymphocytic leukemia [PLL], 1 with PLL, 4 with mantle cell leukemia/lymphoma, 2 with Richter transformation). The overall response rate was 52% (complete remission, 8%; nodular partial response, 4%; partial response, 40%). With a median follow-up of 6.5 months (range, 1-20 months), the median time to progression was 6 months (range, 1-20 months); median survival, 11 months (11+ months for responders vs 6 months for nonresponders). Most toxicities were grade 2 or lower and infusion-related. Infections occurred in 52% of the patients. Cytomegalovirus (CMV) antigenemia assays were positive in 27% of the patients, but only 15% were symptomatic and required therapy. The combination of rituximab and alemtuzumab is feasible, has an acceptable safety profile, and has clinical activity with a short course in a group of patients with poor prognoses.
- Subjects :
- Adult
Aged
Alemtuzumab
Antibodies, Monoclonal administration & dosage
Antibodies, Monoclonal adverse effects
Antibodies, Monoclonal pharmacology
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Murine-Derived
Antibodies, Neoplasm administration & dosage
Antibodies, Neoplasm adverse effects
Antibodies, Neoplasm pharmacology
Antigens, CD immunology
Antigens, CD20 immunology
Antigens, Neoplasm immunology
Antineoplastic Combined Chemotherapy Protocols adverse effects
Apoptosis drug effects
CD52 Antigen
Cytomegalovirus Infections epidemiology
Disease Progression
Feasibility Studies
Female
Glycoproteins immunology
Humans
Infections epidemiology
Lymphoma immunology
Lymphoma mortality
Male
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma immunology
Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality
Recurrence
Remission Induction
Rituximab
Safety
Salvage Therapy
Survival Analysis
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Immunization, Passive
Lymphoma therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0006-4971
- Volume :
- 101
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Blood
- Publication Type :
- Academic Journal
- Accession number :
- 12522009
- Full Text :
- https://doi.org/10.1182/blood-2002-07-1952